Aldape, Kenneth
Princess Margaret Cancer Centre - UHN
Molecular characterization of transcriptional repressor capicua (CIC) in glioblastoma
*co-funded by Brain Canada with the financial support of Health Canada
|
2017/2018 : $98,000
2018/2019 : $98,000
|
Beauregard, Jean-Mathieu
Laval University
Upregulating expression of somatostatin receptors to enhance peptide receptor radionuclide therapy for
neuroendocrine tumours
|
2017/2018 : $45,570
2018/2019 : $75,215
2019/2020 : $75,215
|
Boudreau, Jeanette
Dalhousie University
Development of natural killer cell–based precision immunotherapy for pancreatic cancer
*co-funded with CIHR-ICR
|
2017/2018 : $98,000
2018/2019 : $98,000
|
Chan, Warren
University of Toronto
Increasing nanoparticle tumour delivery efficiency
|
2017/2018 : $97,572
2018/2019 : $97,776
|
Cunningham, Charles
Sunnybrook Research Institute
The feasibility of hyperpolarized 13C-Pyruvate MRI for monitoring patients with intracranial metastasis
*co-funded by Brain Canada with the financial support of Health Canada
|
2017/2018 : $94,938
2018/2019 : $89,057
2019/2020 : $3,920
|
Delisle, Jean-Sebastien
Hôpital Maisonneuve- Rosemont
Resident memory T cells as a new tool for adoptive T-cell therapy
|
2017/2018 : $72,520
2018/2019 : $74,480
2019/2020 : $49,000
|
Di Noia, Javier
Institut de recherches cliniques de Montréal
A novel enzyme capable of metabolizing anticancer deoxycytidine analogs
|
2017/2018 : $66,856
2018/2019 : $66,924
2019/2020 : $62,220
|
Done, Susan
Ontario Cancer Institute/Princess Margaret Cancer Centre
Heterogeneity and immune response in breast cancer
*co-funded with CIHR-ICR
|
2017/2018 : $98,000
2018/2019 : $98,000
|
Geyer, Clarence
University of Saskatchewan
Using synthetic antibody parts to construct antibody-based imaging devices: anti-EGFR molecular targeted imaging
probes for diagnosing and monitoring glioblastoma
*co-funded by Brain Canada with the financial support of Health Canada
|
2017/2018 : $97,968
2018/2019 : $98,000
|
Giguere, Vincent
McGill University
A nuclear mTOR/DNA-PK complex: interaction with chromatin and its impact on prostate cancer
|
2017/2018 : $98,000
2018/2019 : $98,000
|
Gray, Douglas
Ottawa Hospital Research Institute
A novel therapeutic target for metastatic lung cancer
*co-funded with CIHR-ICR
|
2017/2018 : $70,070
2018/2019 : $70,070
2019/2020 : $55,860
|
Hakem, Razqallah
Princess Margaret Cancer Centre - UHN
Breast cancer associated with BRCA1 mutations: synthetic lethality and therapeutic implications
|
2017/2018 : $97,608
2018/2019 : $97,608
|
Hoang, Trang
Université de Montréal
Dual molecular functions of LMO2 as a master oncogene in T-cell acute lymphoblastic leukemia
|
2017/2018 : $98,000
2018/2019 : $98,000
|
Howell, Doris
Princess Margaret Cancer Centre - UHN
Adaptation, feasibility and acceptability study of the advanced symptom monitoring and management system (ASyMS)
mobile health intervention to reduce chemotherapy toxicities in Canadian cancer patients
*co-funded with CIHR-ICR
|
2017/2018 : $98,000
2018/2019 : $98,000
|
Jiang, Xiaoyan
BC Cancer Agency (Vancouver)
Targeting PAK6, a new target gene of miR-185 in drug-insensitive leukemic stem cells
|
2017/2018 : $98,000
2018/2019 : $98,000
|
Kim, Philip
University of Toronto
Developing inhibitors against c-Myc
|
2017/2018 : $96,723
2018/2019 : $96,723
|
Kleinman, Claudia
Jewish General Hospital
Novel biophotonic tools for understanding breast cancer metastasis signalling
|
2017/2018 : $98,000
2018/2019 : $98,000
|
Minchinton, Andrew
BC Cancer Agency (Vancouver)
Delivery and efficacy of targeted monoclonal antibody therapies in cancer: opportunities for therapeutic gains
|
2017/2018 : $97,978
2018/2019 : $97,989
|
Pollak, Michael
Lady Davis Institute
Direct inhibition of mRNA translation for treatment of pancreatic cancer
*co-funded with CIHR-ICR
|
2017/2018 : $96,040
2018/2019 : $96,040
|
Ravi, Ananth
Sunnybrook Research Institute
MOLLI: magnetic occult lesion localization and imaging
|
2017/2018 : $98,000
2018/2019 : $49,000
2019/2020 : $49,000
|
Reimand, Jüri
Ontario Institute for Cancer Research
Integrative discovery of ion channels as drug targets in glioblastoma
*co-funded by Brain Canada with the financial support of Health Canada
|
2017/2018 : $98,000
2018/2019 : $98,000
|
Ross, Colin
University of British Columbia
Preclinical therapeutic development of targeted cardioprotectants for use in cancer patients receiving
anthracycline chemotherapy
|
2017/2018 : $96,883
2018/2019 : $91,473
|
Schmitzer, Andreea
Université de Montréal
New biguanides for mitochondrial accumulation and inhibition of cancer progression
*co-funded with CIHR-ICR
|
2017/2018 : $98,000
2018/2019 : $98,000
|
Sidhu, Sachdev
University of Toronto
Co-targeting sensitizing integrin receptors and oncogenic growth factor receptors in lung cancer with bispecific
antibodies
*co-funded with CIHR-ICR
|
2017/2018 : $98,000
2018/2019 : $98,000
|
Smith, Matthew
Université de Montréal
Real-time surveillance of multiplexed, reversible cancer signalling markers in perturbed RAS networks
*co-funded with CIHR-ICR
|
2017/2018 : $64,190
2018/2019 : $60,711
2019/2020 : $69,139
|
Steidl, Christian
BC Cancer Agency (Vancouver)
Deciphering the cellular crosstalk in the tumour microenvironment of classical Hodgkin lymphoma
|
2017/2018 : $98,000
2018/2019 : $98,000
|
Tai, Isabella
University of British Columbia
Targeting tumour initiating cells in hepatocellular carcinoma to identify novel approaches in patient management
*co-funded with CIHR-ICR
|
2017/2018 : $98,000
2018/2019 : $98,000
|
Tinmouth, Jill
Sunnybrook Research Institute
Can online physician ratings be used to provide meaningful and actionable patient feedback? A mixed methods
feasibility study
|
2017/2018 : $97,020
2018/2019 : $91,875
|
Wan, Yonghong
McMaster University
Enhancement of adoptive cell therapy by oncolytic vaccines
|
2017/2018 : $62,263
2018/2019 : $62,262
2019/2020 : $62,262
|